医学遗传学19遗传疾病的治疗engv.ppt

上传人:wuy****n92 文档编号:80423870 上传时间:2023-03-23 格式:PPT 页数:49 大小:747KB
返回 下载 相关 举报
医学遗传学19遗传疾病的治疗engv.ppt_第1页
第1页 / 共49页
医学遗传学19遗传疾病的治疗engv.ppt_第2页
第2页 / 共49页
点击查看更多>>
资源描述

《医学遗传学19遗传疾病的治疗engv.ppt》由会员分享,可在线阅读,更多相关《医学遗传学19遗传疾病的治疗engv.ppt(49页珍藏版)》请在taowenge.com淘文阁网|工程机械CAD图纸|机械工程制图|CAD装配图下载|SolidWorks_CaTia_CAD_UG_PROE_设计图分享下载上搜索。

1、Medical Genetics19 基因治疗 GeneGene TherapyTherapyMedical Genetics1.What is gene therapy?Genes,which are carried on chromosomes,are the basic physical and functional units of heredity.Genes are specific sequences of bases that encode instructions on how to make proteins.Medical Genetics Although genes

2、get a lot of attention,its the proteins that perform most life functions and even make up the majority of cellular structures.Medical Genetics When genes are altered so that the encoded proteins are unable to carry out their normal functions,genetic disorders can result.Medical Genetics Gene therapy

3、 is a technique for correcting defective genes responsible for disease development.Medical Genetics Researchers may use one of several approaches for correcting faulty genes:1.A normal gene may be inserted into a nonspecific location within the genome to replace a nonfunctional gene.This approach is

4、 most common.2.An abnormal gene could be swapped for a normal gene through homologous recombination.3.The abnormal gene could be repaired through selective reverse mutation,which returns the gene to its normal function.4.The regulation(the degree to which a gene is turned on or off)of a particular g

5、ene could be altered.Medical Genetics2.How does gene therapy work?In most gene therapy studies,a normal gene is inserted into the genome to replace an abnormal,disease-causing gene.Medical Genetics A carrier molecule called a vector must be used to deliver the therapeutic gene to the patients target

6、 cells.Currently,the most common vector is a virus that has been genetically altered to carry normal human DNA.Medical Genetics Viruses have evolved a way of encapsulating and delivering their genes to human cells in a pathogenic manner.Medical Genetics Scientists have tried to take advantage of thi

7、s capability and manipulate the virus genome to remove disease-causing genes and insert therapeutic genes.Medical Genetics Target cells such as the patients liver or lung cells are infected with the viral vector.The vector then unloads its genetic material containing the therapeutic human gene into

8、the target cell.Medical Genetics The generation of a functional protein product from the therapeutic gene restores the target cell to a normal state.Medical GeneticsTo reverse disease caused by genetic damage,researchers isolate normal DNA and package it into a vector,a molecular delivery truck usua

9、lly made from a disabled virus.Doctors then infect a target cell usually from a tissue affected by the illness,such as liver or lung cellswith the vector.The vector unloads its DNA cargo,which then begins producing the missing protein and restores the cell to normal.Medical GeneticsA.Some of the dif

10、ferent types of viruses used as gene therapy vectors(1)Retroviruses A class of viruses that can create double-stranded DNA copies of their RNA genomes.These copies of its genome can be integrated into the chromosomes of host cells.Human immunodeficiency virus(HIV)is a retrovirus.Medical Genetics(2)A

11、denoviruses A class of viruses with double-stranded DNA genomes that cause respiratory,intestinal,and eye infections in humans.The virus that causes the common cold is an adenovirus.(3)Adeno-associated viruses A class of small,single-stranded DNA viruses that can insert their genetic material at a s

12、pecific site on chromosome 19.(4)Herpes simplex viruses A class of double-stranded DNA viruses that infect a particular cell type,neurons.Herpes simplex virus type 1 is a common human pathogen that causes cold sores.Medical GeneticsMedical GeneticsMedical GeneticsMedical Genetics Besides virus-media

13、ted gene-delivery systems,there are several nonviral options for gene delivery.The simplest method is the direct introduction of therapeutic DNA into target cells.This approach is limited in its application because it can be used only with certain tissues and requires large amounts of DNA.Medical Ge

14、netics Another nonviral approach involves the creation of an artificial lipid sphere with an aqueous core.This liposome,which carries the therapeutic DNA,is capable of passing the DNA through the target cells membrane.Medical Genetics Therapeutic DNA also can get inside target cells by chemically li

15、nking the DNA to a molecule that will bind to special cell receptors.Medical Genetics Once bound to these receptors,the therapeutic DNA constructs are engulfed by the cell membrane and passed into the interior of the target cell.This delivery system tends to be less effective than other options.Medi

16、cal Genetics Researchers also are experimenting with introducing a 47th artificial human chromosome into target cells.This chromosome would exist autonomously alongside the standard 46-not affecting their workings or causing any mutations.Medical Genetics It would be a large vector capable of carryi

17、ng substantial amounts of genetic code,and scientists anticipate that,because of its construction and autonomy,the bodys immune systems would not attack it.A problem with this potential method is the difficulty in delivering such a large molecule to the nucleus of a target cell.Medical Genetics3.The

18、 current status of gene therapy research3.The current status of gene therapy research Current gene therapy is experimental and has not proven very successful in clinical trials.Medical Genetics Little progress has been made since the first gene therapy clinical trial began in 1990.In 1999,gene thera

19、py suffered a major setback with the death of 18-year-old Jesse Gelsinger.Medical Genetics Jesse was participating in a gene therapy trial for ornithine transcarboxylase deficiency(OTCD).He died from multiple organ failures 4 days after starting the treatment.His death is believed to have been trigg

20、ered by a severe immune response to the adenovirus carrier.Medical Genetics Another major blow came in January 2003,when the FDA(USA)placed a temporary halt on all gene therapy trials using retroviral vectors in blood stem cells.Medical Genetics FDA(USA)took this action after it learned that a secon

21、d child treated in a French gene therapy trial had developed a leukemia-like condition.Medical Genetics Both this child and another who had developed a similar condition in August 2002 had been successfully treated by gene therapy for X-linked severe combined immunodeficiency disease(X-SCID),also kn

22、own as bubble baby syndrome.Medical Genetics FDAs Biological Response Modifiers Advisory Committee(BRMAC)met at the end of February 2003 to discuss possible measures that could allow a number of retroviral gene therapy trials for treatment of life-threatening diseases to proceed with appropriate saf

23、eguards.FDA has yet to make a decision based on the discussions and advice of the BRMAC meeting.Medical Genetics4.Factors kept gene therapy effectiveA.Short-lived nature of gene therapy Before gene therapy can become a permanent cure for any condition,the therapeutic DNA introduced into target cells

24、 must remain functional and the cells containing the therapeutic DNA must be long-lived and stable.Medical Genetics Problems with integrating therapeutic DNA into the genome and the rapidly dividing nature of many cells prevent gene therapy from achieving any long-term benefits.Patients will have to

25、 undergo multiple rounds of gene therapy.Medical GeneticsB.Immune response Anytime a foreign object is introduced into human tissues,the immune system is designed to attack the invader.Medical Genetics The risk of stimulating the immune system in a way that reduces gene therapy effectiveness is alwa

26、ys a potential risk.Medical Genetics Furthermore,the immune systems enhanced response to invaders it has seen before makes it difficult for gene therapy to be repeated in patients.Medical GeneticsC.Problems with viral vectors Viruses,while the carrier of choice in most gene therapy studies,present a

27、 variety of potential problems to the patient-toxicity,immune and inflammatory responses,and gene control and targeting issues.Medical Genetics In addition,there is always the fear that the viral vector,once inside the patient,may recover its ability to cause disease.Medical GeneticsD.Multigene diso

28、rders Conditions or disorders that arise from mutations in a single gene are the best candidates for gene therapy.Medical Genetics Unfortunately,some the most commonly occurring disorders,such as heart disease,high blood pressure,Alzheimers disease,arthritis,and diabetes,are caused by the combined e

29、ffects of variations in many genes.Medical Genetics Multigene or multifactorial disorders such as these would be especially difficult to treat effectively using gene therapy.Medical Genetics5.Some recent developments University of California,Los Angeles,research team gets genes into the brain using

30、liposomes coated in a polymer call polyethylene glycol(PEG).The transfer of genes into the brain is a significant achievement because viral vectors are too big to get across the blood-brain barrier.This method has potential for treating Parkinsons disease.Medical Genetics RNA interference or gene si

31、lencing may be a new way to treat Huntingtons.Short pieces of double-stranded RNA are used by cells to degrade RNA of a particular sequence.If a siRNA is designed to match the RNA copied from a faulty gene,then the abnormal protein product of that gene will not be produced.Medical GeneticsMedical Ge

32、netics New gene therapy approach repairs errors in messenger RNA derived from defective genes.Technique has potential to treat the blood disorder thalassaemia,cystic fibrosis,and some cancers.Medical Genetics Gene therapy for treating children with X-SCID(sever combined immunodeficiency)or the bubbl

33、e boy disease is stopped in France when the treatment causes leukemia in one of the patients.Medical Genetics Researchers at Case Western Reserve University and Copernicus Therapeutics are able to create tiny liposomes 25 nanometers across that can carry therapeutic DNA through pores in the nuclear

34、membrane.Medical Genetics6.Some of the ethical considerations6.Some of the ethical considerations What is normal and what is a disability or disorder,and who decides?Are disabilities diseases?Do they need to be cured or prevented?Does searching for a cure demean the lives of individuals presently affected by disabilities?Medical GeneticsWho will have access to these therapies?Who will pay for their use?Is somatic gene therapy more or less ethical than germline gene therapy(which is done in egg and sperm cells and prevents the trait from being passed on to further generations)?

展开阅读全文
相关资源
相关搜索

当前位置:首页 > 教育专区 > 大学资料

本站为文档C TO C交易模式,本站只提供存储空间、用户上传的文档直接被用户下载,本站只是中间服务平台,本站所有文档下载所得的收益归上传人(含作者)所有。本站仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。若文档所含内容侵犯了您的版权或隐私,请立即通知淘文阁网,我们立即给予删除!客服QQ:136780468 微信:18945177775 电话:18904686070

工信部备案号:黑ICP备15003705号© 2020-2023 www.taowenge.com 淘文阁